Literature DB >> 12410654

Unresolved issues in prophylaxis.

S A Brown1, L M Aledort, J Astermark, E Berntorp, M van den Berg, V Blanchette, S Donfield, A Gringeri, M Hilgartner, R Kulkarni, C Leissinger, C Negrier, R Nuss, H Petterson, P Petrini, N Poulios, W Schramm.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12410654     DOI： 10.1046/j.1365-2516.2002.00685.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  1 in total

1.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.

Authors:  T E Coyle; M T Reding; J C Lin; L A Michaels; A Shah; J Powell
Journal:  J Thromb Haemost       Date:  2014-04       Impact factor: 5.824
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.